



# List of guidance from ECDC and recent publications on COVID-19

COVID-19 Digest  
15 December 2022

## ECDC Outputs

### Recent publications

**Antiviral resistance monitoring capability and capacity for SARS-CoV-2 and influenza within the EU/EEA**  
Technical report – 15 Dec [Read more »](#)

**ECDC expert consultation on the implementation and evaluation of non-pharmaceutical interventions**  
Technical report – 14 Dec [Read more »](#)

**Integrated respiratory virus surveillance RESPISEVERE and RESPISURV data sets Reporting Protocol Version 1.2** 13 Dec [Read more »](#)

**Coronavirus disease 2019 (COVID-19) data Reporting Protocol Version 6.2** 13 Dec [Read more »](#)

**Intensified circulation of respiratory syncytial virus (RSV) and associated hospital burden in the EU/EEA**  
Risk assessment – 12 Dec [Read more »](#)

**Joint EC, WHO and ECDC statement: Influenza season epidemic kicks off early in Europe as concerns over RSV rise and COVID-19 is still a threat** 01 Dec [Read more »](#)

**Interim analysis of COVID-19 vaccine effectiveness in healthcare workers, an ECDC multi-country study, May 2021–July 2022** Technical report – 21 Nov [Read more »](#)

**Generic protocol for ECDC studies of COVID-19 vaccine effectiveness against confirmed SARS-CoV-2 using healthcare worker cohorts, version 2.0** Technical report – 21 Nov [Read more »](#)

**Interim analysis of COVID-19 vaccine effectiveness against Severe Acute Respiratory Infection due to SARS-CoV-2 in individuals aged 20 years and older – third update** Technical report – 08 Nov [Read more »](#)

### Situation updates on COVID-19

**Joint ECDC-WHO Regional Office for Europe Weekly COVID-19 Surveillance Bulletin** [Read more »](#)

**COVID-19 country overview:** Provides an overview of the evolving epidemiological situation for the EU/EEA (including case/death notification rates, testing rates, test positivity, hospital and ICU occupancy/capacity per country, vaccination uptake at EU/EEA and country level). [Read more »](#)

**COVID-19 situation update worldwide – DISCONTINUED as of 20 June 2022:** You can still access the archived worldwide data on the number of cases and deaths and geographical distribution of 14-day notification rates. [Read more »](#)

For updates, please refer to the [World Health Organization \(WHO\) data on COVID-19](#) and the [WHO Weekly Epidemiological and Weekly Operational Updates page for the non-EU/EEA](#) countries.

**Situation dashboard:** Interactive map with the latest available data on COVID-19 (worldwide). [Read more »](#)  
**DISCONTINUED as of 01 November 2022**

**Vaccine tracker:** Real time data on national vaccine doses distribution and vaccine update within EU/EEA countries. [Read more »](#)

**Maps in support of the Council Recommendation** on a coordinated approach to the restriction of free movement in response to the COVID-19 pandemic in the EU/EEA. **DISCONTINUED.** [Read more »](#)

**Response Measures Database** of ECDC and the Joint Research Centre (JRC) of the European Commission is a regularly updated archive of non-pharmaceutical interventions introduced by 30 countries in the EU/EEA. [Read more »](#)

## Updates on SARS-CoV-2 variants

**SARS-CoV-2 variants of concern:** Overview of the different variants that are currently being considered of concern and of interest as assessed by ECDC. [Read more »](#)

**Variants of concern.** The ECDC country overview includes an own section on variants of concern. It includes e.g. a map of sequencing volume, variant data table and weekly variant distribution by country. [Read more »](#)

**Data on SARS-CoV-2 variants in the EU/EEA.** The downloadable data file contains information about the volume of COVID-19 sequencing, the number and percentage distribution of variants of concern (VOC) by week and country. [Read more »](#)

## Download data on COVID-19

Much of ECDC's data can be downloaded from its website. This for instance includes, but is not limited to, reported number of cases and deaths, 14-day case notification rates, ICU and hospital admissions/occupancy, testing rates/positivity, vaccination data and response measures implemented in EU/EEA countries. [Link to downloadable data»](#)

## Other ECDC Outputs

**ECDC website on COVID-19** – [Read more »](#)

**ECDC surveillance definitions for COVID-19.** [Read more »](#)

**Note that the following pages are no longer updated. A COVID-19 fact sheet will be published in the first quarter of 2023:**

- [Coronaviruses](#)
- [Risk factors and risk groups](#)
- [COVID-19 infection](#)
- [SARS-CoV-2 in children](#)
- [Clinical characteristics of COVID-19](#)
- [Diagnostic testing and screening for SARS-CoV-2](#)
- [Immune responses and immunity to SARS-CoV-2](#)
- [Treatment and pharmaceutical prophylaxis](#)
- [COVID-19 vaccines](#)

**Prevention and control of COVID-19** – how to protect yourself, risk groups, COVID-19 vaccination, patient and case management. [Read more »](#)

**Q & A on COVID-19 aimed at public and lay audience** – Questions and answers. [Read more »](#)

## Infographics, Videos, Webinars and more

**Infographics and leaflets about COVID-19** – Infographics, leaflets and posters on COVID-19. [Read more »](#)

**Videos on COVID-19** – What do we know about the COVID-19. [Read more »](#)

**ECDC Virtual Academy (EVA)** – COVID-19 Micro learning for public health professionals. [Read more »](#)

## Recent peer-reviewed publications

**Disclaimer:** In view of the large number of COVID-19 related publications, this list is compiled based on a rapid review of titles and abstracts and subjective selection of peer-reviewed articles and does not include an additional qualitative assessment or critical appraisal of the evidence by ECDC.

1. Public misperceptions of COVID-19 vaccine effectiveness and waning: experimental evidence from Ireland *Public Health* [Read more »](#)
2. Long-term effects of the interruption of the Dutch breast cancer screening program due to COVID-19: A modelling study *Prev Med* [Read more »](#)
3. Menstrual disturbances in 12- to 15-year-old girls after one dose of COVID-19 Comirnaty vaccine: Population-based cohort study in Norway *Vaccine* [Read more »](#)
4. Bayesian nowcasting with leading indicators applied to COVID-19 fatalities in Sweden *PLoS Comput Biol* [Read more »](#)
5. Relative contribution of essential and non-essential activities to SARS-CoV-2 transmission following the lifting of public health restrictions in England and Wales *Epidemiology and Infection* [Read more »](#)
6. Myocarditis and pericarditis associated with SARS-CoV-2 vaccines: A population-based descriptive cohort and a nested self-controlled risk interval study using electronic health care data from four European countries *Front Pharmacol* [Read more »](#)
7. Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: A prospective test negative case-control study *Lancet Reg Health Eur* [Read more »](#)
8. Natural course of health and well-being in non-hospitalised children and young people after testing for SARS-CoV-2: A prospective follow-up study over 12 months *Lancet Reg Health Eur* [Read more »](#)
9. Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada *CMAJ* [Read more »](#)
10. Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022 *Vaccine* [Read more »](#)
11. Hybrid immunity and protection against infection during the Omicron wave in Malta *Emerg Microbes Infect* [Read more »](#)
12. Experience with Sotrovimab treatment of SARS-CoV-2 infected patients in Denmark *Br J Clin Pharmacol* [Read more »](#)
13. Decline of RSV-specific antibodies during the COVID-19 pandemic *Lancet Infect Dis* [Read more »](#)
14. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study *Lancet Infect Dis* [Read more »](#)
15. Impact of the COVID-19 pandemic on timeliness and equity of measles, mumps and rubella vaccinations in North East London: a longitudinal study using electronic health records *BMJ Open* [Read more »](#)
16. Temporal aspects of unrealistic optimism and robustness of this bias: A longitudinal study in the context of the COVID-19 pandemic *PLoS One* [Read more »](#)
17. Impact of the COVID-19 Vaccination Program on case incidence, emergency department visits, and hospital admissions among children aged 5-17 Years during the Delta and Omicron Periods-United States, December 2020 to April 2022 *PLoS One* [Read more »](#)
18. The WHO estimates of excess mortality associated with the COVID-19 pandemic *Nature* [Read more »](#)

# Additional Resources

## Information from European Institutions, International Organisations and Centres for Disease Control and Prevention

**European Union.** Re-open EU: interactive tool with country information for travel and transportation [Read more »](#)

**European Commission.** Coronavirus response. [Read more »](#)

**European Parliament.** The EU's response to the coronavirus. [Read more »](#)

**EU Healthy Gateways:** [Published guidance and reports for COVID-19](#)

**European Agency for Safety and Health (OSHA).** COVID-19: Resources for the workplace: EU guidance, telework, resources from EU and international organisations. [Read more »](#)

**European Food Safety Authority (EFSA).** COVID-19. [Read more »](#)

**European Medicines Agency (EMA):** Treatments and vaccines for COVID-19. [Latest updates on COVID-19.](#)

**European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).** COVID-19 and drugs. [Read more »](#)

**Health Systems Response Monitor:** [COVID-19 Health System Response Monitor](#) designed in response to the COVID-19 outbreak to collect and organize up-to-date information on how countries are responding to the crisis

**World Health Organization (WHO).** Coronavirus disease (COVID-19) pandemic. [Read more »](#)

**Food and Agriculture Organization of the UN (FAO):** Novel Coronavirus. [Read more »](#)

**African Centres of Disease Control and Prevention.** [Read more »](#)

**Public Health Agency of Canada.** [Read more »](#)

**Chinese Center for Disease Control and Prevention.** [Read more »](#)

**Israel Center for Disease Control, Ministry of Health.** [Read more »](#)

**Korea Disease Control and Prevention Agency.** [Read more »](#)

**Ministry of Health of Mexico.** [Read more »](#)

**UK Health Security Agency.** [Read more »](#)

**US Centers for Disease Control and Prevention.** [Read more »](#)

## COVID-19 information pages of EU/EEA Member States



[Austria »](#)



[Belgium »](#)



[Bulgaria »](#)



[Croatia »](#)



[Cyprus »](#)



[Czechia »](#)



[Denmark »](#)



[Estonia »](#)



[Finland »](#)



[France »](#)



[Germany »](#)



[Greece »](#)



[Hungary »](#)



[Iceland »](#)



[Ireland »](#)



[Italy »](#)



[Latvia »](#)



[Liechtenstein »](#)



[Lithuania »](#)



[Luxembourg »](#)



[Malta »](#)



[Netherlands »](#)



[Norway »](#)



[Poland »](#)



[Portugal »](#)



[Romania »](#)



[Slovakia »](#)



[Slovenia »](#)



[Spain »](#)



[Sweden »](#)

## Living Evidence Summaries

**COAP:** [COVID-19 Open Access Project](#) from the Institute of Social and Preventive Medicine ([ISPM](#)). This database is updated daily with published articles from Pubmed and EMBASE and with preprints from medRxiv and bioRxiv. *(NOTE: last update Feb 2022, no longer updated)*

**COVID-END McMaster Health Forum:** [living evidence syntheses](#) on a variety of topics including efficacy and effectiveness of COVID-19 vaccines in the presence of variants of concern (VOCs).

**EPPI Centre:** [COVID-19](#): a living systematic map of the evidence. Up-to-date map of the current evidence that are partitioned into broad domains for easy exploration.

**MAGIC project (MAGIC Evidence Ecosystem Foundation, theBMJ, WHO):** [Drug treatments for COVID-19](#) living systematic review and network meta-analysis

**WHO living guidelines** on [therapeutics](#), [drugs to prevent COVID-19](#) and [clinical management of COVID-19 patients](#)

**NMA initiative:** [COVID-19 – living initiative](#). Living mapping and living systematic review of Covid-19 trials.

**PregCOV-19LSR** by the University of Birmingham. Series of living systematic reviews (LSR) involving pregnant and postnatal women at risk, suspected, and diagnosed to have COVID-19 according to recommended methods. [Read more »](#) *(NOTE: last update April 2021)*

## Science Updates

**Centre for Evidence-Based Medicine CEBM:** [Oxford COVID-19 Evidence Service](#). Rapid reviews of primary care questions relating to COVID-19.

**Cochrane:** [Cochrane Reviews](#) and related content from the Cochrane Library relating to the COVID-19 pandemic.

**COVID Reference International:** Every day the “Top 10 scientific COVID-19 papers of the day” are presented. Also provides multiple other useful links to literature. [Read more »](#) *(NOTE: last update Jan 2022, no longer updated)*

**Evidence Aid:** [Evidence Collection](#) on Coronavirus (COVID-19). This evidence collection contains plain-language summaries of high-quality research which are available in English, and translated into French, Spanish, Portuguese, Arabic and Chinese (simplified and traditional).

**Health Information and Quality Authority Ireland:** [COVID-19 Publications](#): Clinical evidence summaries and rapid reviews on various topics.

**LitCovid:** [curated literature hub](#) for tracking up-to-date scientific information about COVID-19. It is the most comprehensive resource on the subject, providing a central access a large number of relevant articles in PubMed.

**US Centers for Disease Control and Prevention:** [COVID-19 Science Updates](#) providing brief summaries of new COVID-19-related studies on many topics, including epidemiology, clinical treatment and management, laboratory science, and modeling. The summaries are released every Tuesday and Friday. *(NOTE: last update Dec 2021, no longer updated)*

**VA-ESP COVID-19 Reviews:** [U.S. Veterans’ Affairs \(VA\) Evidence Synthesis Program](#) - Inventory of living systematic reviews and ‘rapid reviews’, with a flag for living reviews and for reviews meeting minimum quality standards

**Wolters Kluwer:** [Clinical effectiveness COVID-19 Resources Available to All](#). View a categorized collection of all UpToDate COVID-19 content including clinical topics, algorithms, patient education and society guideline links.

**World Health Organization:** [COVID-19 Global literature on coronavirus disease](#). Literature database.